Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations have?
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations has 44 citations in the OpenAlex counts ScholarIQ stores.
When was Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations published?
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations has 2018 year in the ScholarIQ index.
What is the open-access status of Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations?
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations has gold oa status in the ScholarIQ index.
What is the DOI of Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations?
The DOI for Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations is on the source record.
What is the PMID of Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations?
The PMID for Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations is on the source record.
What is the OpenAlex record for Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations?
The OpenAlex for Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations is on the source record.